Actuate Therapeutics enters $100M ATM equity offering agreement with B. Riley and Craig-Hallum

ACTUATE THERAPEUTICS, INC.

Agreement allows sale of up to $100M of common stock through agents B. Riley Securities and Craig-Hallum Capital Group.
Sales will be made under existing S-3 shelf registration; agents receive 3.0% commission on gross proceeds.
Offers may be executed as at-the-market, privately negotiated, or block transactions at company's discretion.
Company provides customary indemnification to the sales agents.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.99

ACTUATE THERAPEUTICS, INC. entered into At the Market Issuance Sales Agreement with B. Riley Securities, Inc. and Craig-Hallum Capital Group LLC valued at aggregate offering price of up to $100,000,000 (effective 2025-11-28).

Action: entry
Agreement: atm program
Counterparty: B. Riley Securities, Inc. and Craig-Hallum Capital Group LLC
Value: aggregate offering price of up to $100,000,000
Effective: 2025-11-28

Exact text from the filing

On November 28, 2025, Actuate Therapeutics, Inc. (the “Company”) entered into an At the Market Issuance Sales Agreement (the “Agreement”) with B. Riley Securities, Inc. and Craig-Hallum Capital Group LLC (each a “Sales Agent” and collectively the “Sales Agents”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, $0.000001 par value per share (“Common Stock”), to or through the Sales Agents, as its agents, having an aggregate offering price of up to $100,000,000.

View on SEC.gov

280 material agreements filed in the last 30 days. Browse all material agreements →

ACTUATE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001683168-25-008732

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.